“In the past, M1R was given orally. We are developing a range of novel formulations that will involve a cream applied to the skin on a regular basis. This gets the drug to the nerve endings but limits side effects,” Dr. Fernyhough explained.
There will also be phase 2 proof of concept trials for testing on humans with early signs of diabetic sensorimotor polyneuropathy, with funding in place from the NIH and Canadian Institutes of Health Research (CIHR); these trials are planned within the year and through 2018, in the US, Canada, and Europe.
This study was funded by grants from the JDRF, the Canadian Institutes of Health Research, and the NIH, with support from the St. Boniface Hospital Research Foundation. Dr. Fernyhough and co-author Nigel A. Calcutt, PhD, declare they are directors and shareholders in WinSanTor Inc., which has licensed intellectual property from the University of Manitoba and the University of California, San Diego.